Table 5 Adjusted means with 95% CIs examining the effect of treated nAMD on work productivity and activity impairment after controlling for demographics and health characteristics among currently-treated nAMD patients and matched non-nAMD respondents.
Outcome | Matched non-nAMD | Currently Treated for nAMD | p-value | ||||
|---|---|---|---|---|---|---|---|
N | Mean (SE) | 95% CI | N | Mean (SE) | 95% CI | ||
Absenteeism | 127 | 0.24% (0.28%) | 0.03%, 2.25% | 31 | 18.14% (19.95%) | 2.10%, 100% | < .001 |
Presenteeism | 128 | 12.44% (4.23%) | 6.39%, 24.24% | 33 | 23.89% (9.27%) | 11.17%, 51.10% | 0.05 |
Total work productivity impairment | 127 | 16.24% (5.58%) | 8.28%, 31.83% | 31 | 33.57% (13.40%) | 15.35%, 73.42% | 0.03 |
Total activity impairment | 400 | 24.95% (4.23%) | 17.89%, 34.78% | 100 | 31.70% (6.38%) | 21.36%, 47.04% | 0.12 |
